cabozantinib,nivolumab
exelixis,bms
['rcc,(-irccs),(-srcc),(-urcc)', 'nivo', '9er', 'nivolumab', 'cabozantinib']
vhio s speaks to about #checkmate9er exploratory analysis that she presented at #asco22. nivolumab + cabozantinib achieved deeper responses vs suntitinb in pts with previously untreated advanced #rcc. 
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre